Moderna (MRNA) Equity Average (2017 - 2026)

Moderna (MRNA) has 10 years of Equity Average data on file, last reported at $8.0 billion in Q1 2026.

• Equity Average for Q1 2026 came in at $8.0 billion, down 23.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.0 billion (down 23.41% YoY), and the FY2025 annual result was $9.8 billion, down 21.02% from the prior year.
• Equity Average eased to $8.0 billion in Q1 2026 per MRNA's latest filing, from $9.0 billion in the prior quarter.
• Over five years, Equity Average peaked at $19.0 billion in Q1 2023 and troughed at $8.0 billion in Q1 2026.
• A 5-year average of $13.6 billion and a median of $13.3 billion in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2024: Equity Average jumped 387.89% in 2022, then plunged 31.51% in 2024.
• A 5-year view of Equity Average shows it stood at $18.6 billion in 2022, then dropped by 26.42% to $13.7 billion in 2023, then retreated by 16.41% to $11.4 billion in 2024, then dropped by 21.24% to $9.0 billion in 2025, then fell by 10.69% to $8.0 billion in 2026.
• Business Quant data shows MRNA's Equity Average at $8.0 billion in Q1 2026, $9.0 billion in Q4 2025, and $9.4 billion in Q3 2025.